Ian has been covering a broad range of topics across the Japanese and Asian pharma industry, including corporate, M&A, R&D, pricing and policy developments, since 1988. After a stint as Tokyo-based Japan and Asia editor for Scrip, in 2014 he became managing editor of PharmAsia News (now part of Scrip/Pink Sheet). In his current position, he directs regional coverage for Scrip and Pink Sheet and manages a multinational, on-the-ground team. Ian is a recipient of multiple internal and external awards and a regular participant in APAC conferences, webinars and events, and produces regular podcasts. He has spent the majority of his life in Asia, having grown up in Hong Kong, and enjoys cycling and music.
Latest from Ian Haydock
In this week's episode: Pfizer tops pharma leaderboard; AstraZeneca buys into in vivo cell therapy; Almirall looks to dominate derma spectrum; Incyte’s HS contender looks approvable; and MSD’s Williams says pharma should shorten tech adoption cycles.
In this week's episode: Roche’s big new obesity deal; J&J opts out of next-gen Darzalex; Arvinas and Pfizer’s protein degrader misses Phase III endpoint; Kelun wins first TROP2 ADC approval in lung cancer; and big name brands poised to lose US exclusivity.
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
In this week's episode: low-cost Wegovy an alternative for US self-payers; Bayer rolls up sleeves for turnaround; taking the pulse of NewCo creation; the outlook for Alzheimer’s; and India’s rare disease landscape.
Blackstone to buy leading Japanese CRO in latest move by a global private equity group to build a position in Japan’s life sciences space.
In this week's episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances.